Johannes Fruehauf

Zag Bio is a group of bold scientists and expert drug developers, formed to pioneer thymus-targeted medicines to treat and prevent autoimmune diseases. We have discovered a novel therapeutic approach to restore central immune tolerance by creating bifunctional antibodies that deliver self-antigens to specialized antigen-presenting cells in the thymus. This enables us to harness the body’s natural process for training immune cells to recognize and tolerate self, halting or preventing autoimmune attacks on the body’s own tissues. Zag Bio’s pipeline includes its lead program ZAG-101, a bifunctional antibody that delivers pancreatic beta cell antigens to the thymus to treat Type 1 diabetes, as well as discovery programs for thymus-targeted therapies to address other autoimmune diseases. Zag Bio is located in Cambridge, MA, and is supported by a broad syndicate of life sciences investors. Zag Bio’s team is built on the mission of improving the lives of patients by charting a new direction for better therapies for autoimmune diseases, based on unique insights and understanding of the biology of the thymus.

Developing next generation mRNA immunotherapies

Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease.

Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory disease and organ transplants. Our localized approach represents a significant change from the systemic immunosuppression of conventional medicines, which often have dose-limiting safety concerns and can cause serious infections and cancer. Furthermore, through tissue-specific therapeutic targeting, Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. We aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.

Totient is an AI-driven biotechnology company leveraging tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. Totient reconstructs antibodies from tissues affected by autoimmunity, infections, and cancer collected from patients experiencing exceptional immune responses. Beginning with a population of over 50,000 samples, we have reconstructed antibodies against known and novel extracellular oncology targets: GAGE1, GAGE2A, ANXA1, C4BPB, IL14A, BIRC7, HCLS1, GPR83, and others undisclosed.

Developing next generation mRNA immunotherapies

At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that will forever alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a pipeline with therapeutic candidates that target specific components of ALS and FTD pathology and defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers.

Vaxess Technologies is a venture capital and Gates Foundation-backed life science company developing novel vaccine formulations and delivery technologies based on its proprietary silk platform. We are committed to improving access to vaccines by enabling better, more stable vaccine products that can be easily delivered all over the world. Find more information at www.vaxess.com.

Zag Bio is a group of bold scientists and expert drug developers, formed to pioneer thymus-targeted medicines to treat and prevent autoimmune diseases. We have discovered a novel therapeutic approach to restore central immune tolerance by creating bifunctional antibodies that deliver self-antigens to specialized antigen-presenting cells in the thymus. This enables us to harness the body’s natural process for training immune cells to recognize and tolerate self, halting or preventing autoimmune attacks on the body’s own tissues. Zag Bio’s pipeline includes its lead program ZAG-101, a bifunctional antibody that delivers pancreatic beta cell antigens to the thymus to treat Type 1 diabetes, as well as discovery programs for thymus-targeted therapies to address other autoimmune diseases. Zag Bio is located in Cambridge, MA, and is supported by a broad syndicate of life sciences investors. Zag Bio’s team is built on the mission of improving the lives of patients by charting a new direction for better therapies for autoimmune diseases, based on unique insights and understanding of the biology of the thymus.

The London Startup Network hosts exceptional live and online startup events for start-up founders, entrepreneurs and investors by inviting top-quality guest speakers, hosting Business Networking nights and Pitch Competitions, bringing together some of the most prominent people from across the UK start-up eco-system. While most of our in person startup entrepreneur events London, they are also live streamed to those who are unable to attend in person. StartUp Workshops: Focusing on a specific business area an expert speaker will give a presentation on the essentials for startups followed by a Q&A for your chance to get insights and advice from the pros. Topics include, marketing, PR, legal, finance, fund raising and tech. Founders Roundtables: Building on our ethos of founders helping founders our roundtable startup events bring together entrepreneurs facing similar problems. Whether they operate in a similar vertical, are at the same stage in their life cycle or are solo founders, female founders, remote founders etc. it’s an opportunity to share solutions, boost morale, establish valuable network connections and even make new friends! Investor Lunches: Exclusively by invitation only Investor networking Lunches are curated startup events specifically for bringing together our most prominent and active investors with startups which meet their investor profile. As you can imagine these are high demand events at exclusive London locations and attendees are carefully vetted to make sure they are value added experiences for all involved.

We are biotech venture builders and drug developers with decades of experience in cell & gene therapies. We have created a novel model to unlock innovation in this transformative space, delivering life-saving treatments and making them accessible to patients worldwide

Developing next generation mRNA immunotherapies

Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease.